Denmark· DK-28107655326
Zafrilla
A dienogest product containing dienogest, registered in Denmark by Paranova Danmark A/S. The same ATC class is registered in 16 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Dienogest is registered in 16 of 19 countries.
Countries holding a registration under ATC G03DB08 (dienogest), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Dienogest · ATC G03DB08
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of dienogest costs, country by country.
Normalised to the WHO defined daily dose (2 mg), the median price runs from $0.48 in France to $3.02 in Switzerland — a ×6.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dienogest · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.02
- IT Italy$0.69
- FR France$0.48
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- DIENOGEST
- Manufacturer
- Paranova Danmark A/S
- Country
- Denmark (DK)
- ATC code
- G03DB08
- ATC class
- Dienogest
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107655326
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
54 interactions on record for dienogest.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dienogest · interactions on record
54 records
- 12 severe
- 38 moderate
- 4 minor
Most severe, free to view
- GriseofulvinD01AA08severe
- GriseofulvinD01BA01severe
- DabrafenibL01EC02severe
- EncorafenibL01EC03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G03DB08
Dienogest, as other registers publish it.
- PolandAridyaAristo Pharma Sp. z o.o.
- CzechiaARIDYAAristo Pharma GmbH, Berlin
- CzechiaARIDYAAristo Pharma GmbH, Berlin
- CzechiaARIDYAAristo Pharma GmbH, Berlin
- CzechiaARIDYAAristo Pharma GmbH, Berlin
- CanadaASPEN-DIENOGESTASPEN PHARMACARE CANADA INC.
- ItalyDEVICIUSSTRAGEN NORDIC A/S
- ItalyDEVICIUSSTRAGEN NORDIC A/S
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca634ee1-85d4-4bc9-b79f-0ca546a0b5f0 GET /v1/drugs/ca634ee1-85d4-4bc9-b79f-0ca546a0b5f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "tabletter",
"source": "dkma",
"strength": "2 mg",
"auth_role": "DKMA",
"dk_drugid": "28107655326",
"substance": "DIENOGEST",
"auth_procedure": "Par-Imp",
"in_medicinpriser": false,
"registration_date_serial": "46281"
}See everything about dienogest.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.